SUTRO BIOPHARMA, INC. Interest Expense on Debt
SUTRO BIOPHARMA, INC. (STRO) reported Interest Expense on Debt of $1.30 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-25.
Discontinued › Expense Statement › Interest Expense
us-gaap:InterestExpenseDebt · last filed 2024-03-25
- SUTRO BIOPHARMA, INC. interest expense, debt for the quarter ending 2023-12-31 was $200.00K, a 66.67% decline year-over-year.
- SUTRO BIOPHARMA, INC. interest expense, debt for the quarter ending 2023-09-30 was $300.00K, a 50.00% decline year-over-year.
- SUTRO BIOPHARMA, INC. interest expense, debt for the quarter ending 2023-06-30 was $400.00K, a 33.33% decline year-over-year.
- SUTRO BIOPHARMA, INC. interest expense, debt for the quarter ending 2023-03-31 was $500.00K, a 28.57% decline year-over-year.
- SUTRO BIOPHARMA, INC. interest expense, debt for fiscal 2023 was $1.30M, a 45.83% decline from fiscal 2022.
- SUTRO BIOPHARMA, INC. interest expense, debt for fiscal 2022 was $2.40M, a 7.69% decline from fiscal 2021.
- SUTRO BIOPHARMA, INC. interest expense, debt for fiscal 2021 was $2.60M, a 13.04% increase from fiscal 2020.
- SUTRO BIOPHARMA, INC. interest expense, debt for fiscal 2020 was $2.30M, a 109.09% increase from fiscal 2019.
| Period end | Interest Expense, Debt 3 month | Interest Expense, Debt 6 month | Interest Expense, Debt 9 month | Interest Expense, Debt 12 month |
|---|---|---|---|---|
| 2023-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $500.00K derived: sum of 2 quarters · filed 2024-03-25 | $900.00K derived: sum of 3 quarters · filed 2024-03-25 | $1.30M 10-K · filed 2024-03-25 |
| 2023-09-30 | $300.00K 10-Q · filed 2023-11-13 | $700.00K derived: sum of 2 quarters · filed 2023-11-13 | $1.10M 10-Q · filed 2023-11-13 | $1.80M derived: sum of 4 quarters · filed 2024-03-25 |
| 2023-06-30 | $400.00K 10-Q · filed 2023-08-10 | $800.00K 10-Q · filed 2023-08-10 | $1.50M derived: sum of 3 quarters · filed 2024-03-25 | $2.10M derived: sum of 4 quarters · filed 2024-03-25 |
| 2023-03-31 | $500.00K 10-Q · filed 2023-05-15 | $1.10M derived: sum of 2 quarters · filed 2024-03-25 | $1.70M derived: sum of 3 quarters · filed 2024-03-25 | $2.30M derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $1.20M derived: sum of 2 quarters · filed 2024-03-25 | $1.80M derived: sum of 3 quarters · filed 2024-03-25 | $2.40M 10-K · filed 2024-03-25 |
| 2022-09-30 | $600.00K 10-Q · filed 2023-11-13 | $1.20M derived: sum of 2 quarters · filed 2023-11-13 | $1.80M 10-Q · filed 2023-11-13 | $2.60M derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-06-30 | $600.00K 10-Q · filed 2023-08-10 | $1.30M 10-Q · filed 2023-08-10 | $2.00M derived: sum of 3 quarters · filed 2024-03-25 | $2.70M derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-03-31 | $700.00K 10-Q · filed 2023-05-15 | $1.40M derived: sum of 2 quarters · filed 2024-03-25 | $2.10M derived: sum of 3 quarters · filed 2024-03-25 | $2.70M derived: sum of 4 quarters · filed 2024-03-25 |
| 2021-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $1.40M derived: sum of 2 quarters · filed 2024-03-25 | $2.00M derived: sum of 3 quarters · filed 2024-03-25 | $2.60M 10-K · filed 2024-03-25 |
| 2021-09-30 | $700.00K 10-Q · filed 2022-11-08 | $1.30M derived: sum of 2 quarters · filed 2022-11-08 | $1.90M 10-Q · filed 2022-11-08 | $2.50M derived: sum of 4 quarters · filed 2023-03-30 |
| 2021-06-30 | $600.00K 10-Q · filed 2022-08-08 | $1.30M 10-Q · filed 2022-08-08 | $1.80M derived: sum of 3 quarters · filed 2023-03-30 | $2.50M derived: sum of 4 quarters · filed 2023-03-30 |
| 2021-03-31 | $600.00K 10-Q · filed 2022-05-09 | $1.20M derived: sum of 2 quarters · filed 2023-03-30 | $1.90M derived: sum of 3 quarters · filed 2023-03-30 | $2.50M derived: sum of 4 quarters · filed 2023-03-30 |
| 2020-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $1.30M derived: sum of 2 quarters · filed 2023-03-30 | $1.90M derived: sum of 3 quarters · filed 2023-03-30 | $2.30M 10-K · filed 2023-03-30 |
| 2020-09-30 | $700.00K 10-Q · filed 2021-11-10 | $1.30M derived: sum of 2 quarters · filed 2021-11-10 | $1.70M 10-Q · filed 2021-11-10 | $1.70M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $600.00K 10-Q · filed 2021-08-09 | $1.00M 10-Q · filed 2021-08-09 | $1.00M derived: sum of 3 quarters · filed 2022-02-28 | $1.30M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $200.00K 10-Q · filed 2021-05-07 | $400.00K derived: sum of 2 quarters · filed 2022-02-28 | $700.00K derived: sum of 3 quarters · filed 2022-02-28 | $1.00M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $500.00K derived: sum of 2 quarters · filed 2022-02-28 | $800.00K derived: sum of 3 quarters · filed 2022-02-28 | $1.10M 10-K · filed 2022-02-28 |
| 2019-09-30 | $300.00K 10-Q · filed 2020-11-05 | $600.00K derived: sum of 2 quarters · filed 2020-11-05 | $900.00K 10-Q · filed 2020-11-05 | $1.70M derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-06-30 | $300.00K 10-Q · filed 2020-08-06 | $600.00K 10-Q · filed 2020-08-06 | $1.40M derived: sum of 3 quarters · filed 2021-03-18 | $1.70M derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-03-31 | $400.00K 10-Q · filed 2020-05-11 | $1.10M derived: sum of 2 quarters · filed 2021-03-18 | $1.40M derived: sum of 3 quarters · filed 2021-03-18 | $1.70M derived: sum of 4 quarters · filed 2021-03-18 |
| 2018-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $1.00M derived: sum of 2 quarters · filed 2021-03-18 | $1.30M derived: sum of 3 quarters · filed 2021-03-18 | $1.60M 10-K · filed 2021-03-18 |
| 2018-09-30 | $300.00K 10-Q · filed 2019-11-08 | $600.00K derived: sum of 2 quarters · filed 2019-11-08 | $900.00K 10-Q · filed 2019-11-08 | |
| 2018-06-30 | $300.00K 10-Q · filed 2019-08-14 | $600.00K 10-Q · filed 2019-08-14 | ||
| 2018-03-31 | $400.00K 10-Q · filed 2019-05-15 | |||
| 2017-12-31 | $600.00K 10-K · filed 2020-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |